Kyowa Kirin (TSE:4151), What Is Behind The Fresh Attention?

Kyowa Kirin (TSE:4151) just released final data from the German MINT study on its lymphoma drug mogamulizumab, highlighting real world clinical benefits that investors now need to weigh against the stock’s recent performance.

At a share price of ¥2,222.5, Kyowa Kirin has seen only modest short term share price moves. The 90 day share price return has fallen 15.8% and the 5 year total shareholder return is down 32.94%, suggesting longer term momentum has cooled despite the recent mogamulizumab data.

Spot opportunities across oncology and healthcare by scanning our hand picked 9 healthcare AI stocks that could be setting up their next breakout on clinical or data readouts.

Kyowa Kirin now pairs modest recent share declines with fresh real world data on mogamulizumab. Does that mix still tilt the risk reward toward buyers once valuation enters the frame?

Price-to-Earnings of 14.3x: Is it justified?

Valuation work on Kyowa Kirin points to a mixed picture, with a discounted cash flow view suggesting upside while the current P/E of 14.3x appears slightly rich versus the domestic pharmaceuticals group.

The P/E ratio compares what investors pay today for each unit of earnings. For a drug developer like Kyowa Kirin, this measure is directly related to how the market is pricing current profit against the pipeline and existing product base.

On one side, Kyowa Kirin trades at 14.3x earnings, which is a touch higher than the 13.9x average for the JP Pharmaceuticals industry. On the other side, Simply Wall St’s fair P/E estimate sits at 20.8x, a level that is materially higher than where the shares change hands today and represents a valuation the market could potentially move toward if earnings quality and growth forecasts hold.

Explore the SWS fair ratio for Kyowa Kirin.

Result: Price-to-Earnings of 14.3x (UNDERVALUED).

Still, the story can change quickly if key pipeline trials stumble or if Kyowa Kirin’s longer term shareholder returns, which have declined over 5 years, weigh further on sentiment.

Find out about the key risks to this Kyowa Kirin narrative.

Another View: What The DCF Says About Kyowa Kirin

The market is paying a P/E of 14.3x for Kyowa Kirin, yet our DCF model points to a future cash flow value of ¥3,679.22 per share versus a current price of ¥2,222.5. That gap implies the stock screens as undervalued on cash flows even if earnings multiples look only modestly attractive. Which signal should serve as the anchor?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kyowa Kirin for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 12 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on Kyowa Kirin so far, right, with valuation and drug data pulling in different directions while the share price drifts. If you want to move quickly and base your call on more than headlines, it is worth checking how the market is weighing those potential upsides in the 4 key rewards.

Looking for more Kyowa Kirin investment ideas?

If Kyowa Kirin has sharpened your focus on pricing, cash flows and risks, broaden your watchlist with a few targeted stock ideas built from clear fundamentals.

• Spot potential mispricings by scanning a focused set of quality companies with upside signals in the 12 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that offer resilient payouts through the 28 dividend fortresses.
• Lower portfolio stress by checking companies with robust finances using the list of solid balance sheet and fundamentals (21 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com